Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTPW) Return on Capital Employed (2023 - 2025)

Historic Return on Capital Employed for 60 Degrees Pharmaceuticals (SXTPW) over the last 3 years, with Q3 2025 value amounting to 2.44%.

  • 60 Degrees Pharmaceuticals' Return on Capital Employed fell 3500.0% to 2.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.44%, marking a year-over-year decrease of 3500.0%. This contributed to the annual value of 1.9% for FY2024, which is 11200.0% up from last year.
  • 60 Degrees Pharmaceuticals' Return on Capital Employed amounted to 2.44% in Q3 2025, which was down 3500.0% from 2.27% recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' Return on Capital Employed's 5-year high stood at 0.68% during Q3 2023, with a 5-year trough of 2.53% in Q1 2025.
  • Moreover, its 3-year median value for Return on Capital Employed was 1.97% (2024), whereas its average is 1.72%.
  • Over the last 5 years, 60 Degrees Pharmaceuticals' Return on Capital Employed had its largest YoY gain of -3500bps in 2025, and its largest YoY loss of -17300bps in 2025.
  • Over the past 3 years, 60 Degrees Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.92% in 2023, then tumbled by -115bps to 1.97% in 2024, then dropped by -24bps to 2.44% in 2025.
  • Its Return on Capital Employed stands at 2.44% for Q3 2025, versus 2.27% for Q2 2025 and 2.53% for Q1 2025.